Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MERAMIRT is a sterile ophthalmic solution formulated as a Class IIa medical device for the management of dry eye disease and ocular surface disorders. It contains a combination of hypromellose (hydroxypropyl methylcellulose) and inositol. Hypromellose acts as a lubricant and viscosity-enhancing agent that stabilizes the tear film and increases the contact time of the solution on the ocular surface. Inositol is included to support ocular surface hydration and assist in the management of symptoms associated with asthenopia (eye strain) and accommodative effort. The product is indicated for the hydration and lubrication of the ocular surface under conditions of stress caused by environmental, visual, or mechanical factors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hypromellose + inositol.